» Articles » PMID: 38999218

Nutritional Trends in Cystic Fibrosis: Insights from the Italian Cystic Fibrosis Patient Registry

Overview
Journal J Clin Med
Specialty General Medicine
Date 2024 Jul 13
PMID 38999218
Authors
Affiliations
Soon will be listed here.
Abstract

Over the past decades, efforts have been made to improve the nutritional well-being of people with cystic fibrosis (pwCF). Due to the correlation observed between nutritional indices and lung function, prevailing recommendations consistently advocate for BMI percentile goals at or above the 50th percentile in pwCF. Recent global trends show a notable increase in overweight and obese statuses among pwCF. This study aims to explore the nutritional status of Italian pwCF. Data from the Italian CF Patient's Registry were analysed to assess the proportion of individuals categorized as underweight, target weight, overweight, and obese from 2010 to 2021. Patient-level comparison data from 2021 were also examined to identify the potential determinants of overweight and obesity. Analysis spanning 2010 to 2021 reveals a decrease of approximately 40% in underweight status among adults, while the proportion of malnourished patients younger than 18 years remained stable. Conversely, there was a substantial increase of over 70% in overweight status and over 85% in obesity among adults, with minor fluctuations observed among children and adolescents. Patient factors associated with increased obesity incidence included age older than 45 years, male gender, pancreatic sufficiency, possession of at least one CFTR variant conferring residual function, ppFEV > 90, and lower prevalence of colonization. Our study confirms the evolving nutritional status landscape among Italian adult pwCF, with a significant shift towards overweight and obesity over the past decade. These trends highlight the need for proactive measures within CF standards of care to adapt and address the changing needs of patients.

Citing Articles

A Global Perspective on Transition Models for Pediatric to Adult Cystic Fibrosis Care: What Has Been Made So Far?.

Poamaneagra S, Plesca D, Tataranu E, Marginean O, Nemtoi A, Mihai C J Clin Med. 2024; 13(23).

PMID: 39685886 PMC: 11642410. DOI: 10.3390/jcm13237428.


Is Obesity a Problem in New Cystic Fibrosis Treatments?.

Solis-Garcia M, Garcia-Clemente M, Madrid-Carbajal C, Pelaez A, Punter R, Bachiller J Nutrients. 2024; 16(18).

PMID: 39339703 PMC: 11435113. DOI: 10.3390/nu16183103.

References
1.
Taylor-Cousar J, Robinson P, Shteinberg M, Downey D . CFTR modulator therapy: transforming the landscape of clinical care in cystic fibrosis. Lancet. 2023; 402(10408):1171-1184. DOI: 10.1016/S0140-6736(23)01609-4. View

2.
Stallings V, Stark L, Robinson K, Feranchak A, Quinton H . Evidence-based practice recommendations for nutrition-related management of children and adults with cystic fibrosis and pancreatic insufficiency: results of a systematic review. J Am Diet Assoc. 2008; 108(5):832-9. DOI: 10.1016/j.jada.2008.02.020. View

3.
Duckers J, FitzGerald R, Proud D, Addy C, Datta D . Forewarned is forearmed: The cardiovascular time bomb in Cystic Fibrosis. J Cyst Fibros. 2021; 21(3):551-552. DOI: 10.1016/j.jcf.2021.11.008. View

4.
Bass R, Brownell J, Stallings V . The Impact of Highly Effective CFTR Modulators on Growth and Nutrition Status. Nutrients. 2021; 13(9). PMC: 8470943. DOI: 10.3390/nu13092907. View

5.
Gramegna A, Aliberti S, Contarini M, Savi D, Sotgiu G, Majo F . Overweight and obesity in adults with cystic fibrosis: An Italian multicenter cohort study. J Cyst Fibros. 2021; 21(1):111-114. DOI: 10.1016/j.jcf.2021.05.002. View